Clinical Data AZ claims another win for Imfinzi in frontline liver cancer PharmaphorumAstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.Clinical DataOncologyRead full story pharminent April 2, 2026 (Last updated: April 2, 2026) Pharmaphorum AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme. Clinical DataOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesityNext: Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
